EXTENSION OF OFFERS
As announced on 8 February 2019, the Company has entered into an agreement with BioHealth Pharmaceuticals Pty Ltd and restructured its transaction with Medcan Australia Pty Ltd. Following consultation with the ASX, the Company is required to prepare further documentation, re-seek shareholder approval for the transactions and issue an updated prospectus. These documents are currently being prepared. The Company currently expects the relisting process to take approximately 6 weeks primarily to allow for the calling of the extraordinary general meeting to obtain the required new shareholder approval of the transactions. The Company will issue a further update confirming the new expected timetable as soon as possible.
As a result, the Company has decided to extend the Offers to 25 March 2019.
This date is indicative only and may change without notice. The Company reserves the right to close the Offers early or extend the closing dates of the Offers without prior notice. The Company also reserves the right not to proceed with the Offers at any time before the issue of Securities to Applicants.
- Forums
- ASX - By Stock
- CGB
- Ann: Twelfth Supplementary Prospectus
Ann: Twelfth Supplementary Prospectus, page-20
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online